FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL									
	OMB Number:	3235-0287								
l	Estimated average burde	en								
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar	RI	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS									Relationship of Reporting Person(s) to Issuer (Check all applicable)									
GOLDSTEIN JOSEPH L							INC [REGN]								X	Direc		10% (
(Loot)		(Firs		Middle)		_										Officer (give title below)		Other (specify below)		
(Last)		`	,	,			3. Date of Earliest Transaction (Month/Day/Year)									belot	•)	below	, l	
777 OLE	SAW M	08/	08/23/2013																	
								4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) 10591														X	Form	Form filed by One Reporting Person				
														Form filed by More than One Reporting						
(City) (State) (Zip)															Person					
			Tabl	e I - N	on-Deriv	ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or B	enefic	ially	Owne	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/							Execution Date,			3. Transaction Code (Instr. 8) 4. Securities A Disposed Of (s Acquired (A) or f (D) (Instr. 3, 4 aı		nd 5) Secu Bene		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount	(A) or (D)	Price		Transa	action(s) 3 and 4)		(Instr. 4)	
Common	2013	13		S		1,000	D	\$238	.29(1)		4,000	D								
			Та	ble II								osed of, convertib			-	vned				
1. Title of Derivative Security (Instr. 3)				4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of		t		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

1. Represents volume-weighted average price of sales of 1,000 shares of Company stock on August 23, 2013 at prices ranging from \$238.19 to \$238.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2013 at each separate price.

/s/**Joseph L. Goldstein 08/23/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.